Results 61 to 70 of about 67,305 (212)

Induction of IL-12 Production in Human Peripheral Monocytes by Trypanosoma cruzi Is Mediated by Glycosylphosphatidylinositol-Anchored Mucin-Like Glycoproteins and Potentiated by IFN-γ and CD40-CD40L Interactions

Mediators of Inflammation, 2014
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is characterized by immunopathology driven by IFN-γ secreting Th1-like T cells. T.
Lúcia Cristina Jamli Abel, Ludmila Rodrigues Pinto Ferreira, Isabela Cunha Navarro, Monique Andrade Baron, Jorge Kalil, Ricardo Tostes Gazzinelli, Luiz Vicente Rizzo, Edecio Cunha-Neto   +7 more
doaj   +1 more source

Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection [PDF]

, 2016
Prevention of Trypanosoma cruzi infection in mammals likely depends on either prevention of the invading trypomastigotes from infecting host cells or the rapid recognition and killing of the newly ...
Bustamante, Juan Manuel, Tarleton, Rick
core   +1 more source

The Contribution of Entomological Surveillance to the Control of Chagas Disease in Endemic Regions: An Integrative Literature Review

Tropical Medicine &International Health, EarlyView.
ABSTRACT Chagas disease remains a significant public health challenge in various endemic regions of Latin America. The persistence of vector‐borne transmission highlights the complexity of the issue and the limitations of traditional strategies. In this context, entomological surveillance plays a strategic and multifaceted role, not only in the early ...
Daniel Rodrigo de Lima Gomes, Gilliard do Nascimento, Pedro Mariano da Silva Rodrigues, Ana Beatriz da Silva, Ysabele Yngrydh Valente Silva, Ekarinny Myrela Brito de Medeiros, Cléber de Mesquita Andrade, Thales Allyrio Araújo de Medeiros Fernandes, José Antonio da Silva Júnior, Ellany Gurgel Cosme do Nascimento   +9 more
wiley   +1 more source

Scalable Access to N‑Acylindole Linkages: Enabling the Synthesis of Antitrypanosomal Noncanonical Cyclic Peptides for Chagas Disease

Angewandte Chemie, Volume 138, Issue 15, 6 April 2026.
A gram‐scale supply of bulbiferamide A, which features a rare N‐acylindole linkage and possesses potent inhibitory activity against Trypanosoma cruzi epimastigotes (IC50 = 4.1 µM)—the causative parasite of Chagas disease—was successfully achieved. Moreover, the cyclization strategy developed in this study facilitated the synthesis of noncanonical ...
Jie Zhang, Hugh Nakamura
wiley   +2 more sources

Analyses of 32 loci clarify phylogenetic relationships among Trypanosoma cruzi lineages and support a single hybridization prior to human contact. [PDF]

PLoS Neglected Tropical Diseases, 2011
The genetic diversity of Trypanosoma cruzi, the etiological agent of Chagas disease, has been traditionally divided in two major groups, T. cruzi I and II, corresponding to discrete typing units TcI and TcII-VI under a recently proposed nomenclature. The
Carlos A Flores-López, Carlos A Machado
doaj   +1 more source

Recombinant LPG3 Protein From Leishmania chagasi as an Antigen for the Diagnosis of Canine Visceral Leishmaniasis

Tropical Medicine &International Health, EarlyView.
ABSTRACT Visceral leishmaniasis (VL) is a human neglected tropical disease in which dogs participate as reservoirs of the etiological agent Leishmania chagasi. The identification of infected dogs is important to the control of VL, and recombinant proteins are strong antigen candidates for canine visceral leishmaniasis (CVL) serodiagnosis. In this work,
Thaís Viana Fialho Martins, Anna Cláudia Alves de Souza, Bianca Meireles Miranda, Ronny Francisco de Souza, Daniel Silva Sena Bastos, Neverton José Silva Ferreira, Tiago Antônio de Oliveira Mendes, Celeste da Silva Freitas de Souza, George Luiz Lins Machado‐Coelho, Maria Terezinha Bahia, Leandro Licursi de Oliveira, Juliana Lopes Rangel Fietto, Eduardo de Almeida Marques‐da‐Silva   +12 more
wiley   +1 more source

Novel cruzain inhibitors for the treatment of Chagas' disease. [PDF]

, 2012
The protozoan parasite Trypanosoma cruzi, the etiological agent of Chagas' disease, affects millions of individuals and continues to be an important global health concern.
Arkin, Michelle R, Doak, Allison, Durrant, Jacob D, Keränen, Henrik, McCammon, J Andrew, Ratnam, Joseline, Rogers, Kathleen E   +6 more
core   +1 more source

Should Trypanosoma cruzi be called "cruzi" complex? A review of the parasite diversity and the potential of selecting population after in Vitro culturing and mice infection

Memorias do Instituto Oswaldo Cruz, 2003
Morpho-biological diversity of Trypanosoma cruzi has been known since Chagas' first works in 1909. Several further studies confirmed the morphological differences among the parasite strains, which were isolated from different reservoirs and vectors, as ...
Devera Rodolfo, Fernandes Octavio, Coura José Rodrigues   +2 more
doaj   +3 more sources

Sialic Acid Glycobiology Unveils Trypanosoma cruzi Trypomastigote Membrane Physiology. [PDF]

, 2016
Trypanosoma cruzi, the flagellate protozoan agent of Chagas disease or American trypanosomiasis, is unable to synthesize sialic acids de novo. Mucins and trans-sialidase (TS) are substrate and enzyme, respectively, of the glycobiological system that ...
A Acosta-Serrano, A Buschiazzo, A Egner, A Galetovic, Andrés B. Lantos, AS Couto, BB Diaz-Rohrer, Beatriz Araoz, CA Buscaglia, CA Buscaglia, Carlos A. Buscaglia, Carolyn R. Bertozzi, DC Bartholomeu, E Bayer-Santos, EJ Finkelsztein, G Bernabo, Giannina Carlevaro, GM Rocha, GM Rocha, GT Dempsey, H Yu, Hai Yu, HT McMahon, HT McMahon, I Levental, I Urban, IA Oliveira, IC Almeida, IC Almeida, J Folling, J Zimmerberg, JA Prescher, JA Prescher, JC Jewett, JH Lumb, JM Baskin, JM Di Noia, JM Di Noia, Juan Mucci, K Simons, KM Tyler, LM De Pablos, LM Freitas, M Hashimoto, Malcolm J. McConville, Mariano Bossi, María de los Milagros Camara, MdL Camara, ME Giorgi, MF Goncalves, MG Risso, ML Salto, MM Camargo, MS Leguizamón, MV Gudheti, NM Quanquin, NW Andrews, Oscar Campetella, P Ruiz Diaz, Pablo Ruiz Diaz, PN Ulrich, RE Thompson, RM de Lederkremer, RP Muiá, S Niyogi, S Schenkman, S Schenkman, S Schenkman, S Tomlinson, SS Rubin de Celis, T Furuya, TJ Gould, Torrecilhas AC Trocoli, U Frevert, V de Paulo Martins, V Jimenez, VA Campo, Vde P Martins, VL Pereira-Chioccola, W de Souza, W de Souza, WB Huttner, X Xu, Xi Chen   +83 more
core   +5 more sources

Exploring 6‐Hydroxy‐3‐Aryl/Heteroarylcoumarins as Promising Candidates Against Trypanosoma cruzi

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
New therapies are urgently needed for Chagas disease, and screening of 6‐hydroxy‐3‐aryl/heteroarylcoumarin derivatives identified highly selective compounds with potent activity against T. cruzi. In particular, derivative 1f showed submicromolar trypomastigote potency, dual‐stage activity, and inhibition of amastigote‐to‐trypomastigote differentiation,
C. N. Pereira, L. da Silva Lara, S. da Costa Lanera, T. Pérez de Souza, M. C. de Souza Pereira, G. L. Delogu, M. Silva dos Santos, M. J. Matos   +7 more
wiley   +1 more source